Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : CELSION CORP. (CLN was CELN) UP $.33 TO $.59 ON HUGE NEWS -- Ignore unavailable to you. Want to Upgrade?

To: Stock Master who wrote (491)	8/16/1999 1:32:00 PM
From: C Horn	Read Replies (1) \| Respond to of 518

Monday August 16, 1:01 pm Eastern Time Company Press Release Celsion Receives FDA Approval for Phase I Breast Ablation Trials At Two New Sites -- Evaluation to be Accelerated via Studies to be Conducted at UCLA and Columbia (FL) -- COLUMBIA, Md.--(BW HealthWire)--Aug. 16, 1999-- Celsion Corp. (OTC BB:CELN - news) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) to commence Phase I clinical studies at two new sites to evaluate the Company's focused heat breast cancer treatment system. To expedite patient accrual, the Company explained, trials are planned at Columbia Hospital in West Palm Beach, Florida, a member of Columbia/HCA Healthcare Corp., and Harbor UCLA Medical Center in Torrance, California. Celsion said the studies should begin as soon as the hospitals receive internal approval. Investigators: The principal investigator of the Phase I clinical evaluations is Dr. Hernan Vargas, Chief of Surgical Oncology at Harbor UCLA Medical Center. The three co-investigators are Dr. Jerome Block, Professor of Medicine and member of the Division of Medical Oncology and Hematology at Harbor UCLA, Dr. Robert Gardner, Chief of the Center for Breast Surgery at Columbia Hospital, and Dr. Charles Vogel, Medical Director of Columbia Cancer Research Network. Celsion hopes to evaluate the ability of its breast cancer treatment focused heat technology to destroy cancerous tumors and viable cancer cells in humans using heat alone. The device is designed to provide non-surgical, minimally invasive treatment and is hoped to be non-toxic and side effect free. MIT Origin of Technology: The Company's breast cancer treatment incorporates a focused heat system developed by Celsion using proprietary technologies licensed exclusively from several engineering and medical research institutions. This includes the Adaptive Phased Array (APA) focusing technology, which the Massachusetts Institute of Technology (MIT) designed for the U.S. Department of Defense Star Wars Initiative that Celsion has adapted with the intent of focusing microwave heat on tumors while leaving healthy skin and surrounding tissue unharmed. Celsion Corporation is a research and development company dedicated to commercializing medical treatment systems for cancer and benign prostatic hyperplasia using focused heat delivered by patented microwave technology. Clinicals and further development of the Company's treatment systems are being conducted by leading institutions such as the Columbia Hospital (a Columbia/HCA Healthcare member), Duke University, Harbor UCLA Medical Center, Massachusetts Institute of Technology, and Montefiore Medical Center. Forward-looking statements in this release are made pursuant to the ''safe harbor'' provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including, without limitation, possible changes in cost of materials, expense items, capital expenditures, capital structure, and other financial items; introduction of new products and possible acquisitions of assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission. -------------------------------------------------------------------------------- Contact: Celsion Corporation John Mon (410) 290-5390 www.celsion.com or OTC Financial Network Geoffrey Eiten (888) 399-7541 ext. 13 www.otcfn.com/celn

To: Stock Master who wrote (491)	8/27/1999 1:52:00 AM
From: chirodoc	Respond to of 518

what other companies are doing thermotherapy? what is the competition? curtis

To: Stock Master who wrote (491)	8/28/1999 10:55:00 AM
From: chirodoc	Respond to of 518

heat controls eye cancer "This treatment provides satisfactory control for selected retinoblastomas, with 86% of tumors demonstrating lasting regression." Arch Ophthalmol 1999 Jul;117(7):885-93 Thermotherapy for retinoblastoma. Shields CL, Santos MC, Diniz W, Gunduz K, Mercado G, Cater JR, Shields JA Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, PA 19107, USA. OBJECTIVE: To evaluate the results of thermotherapy for retinoblastoma. DESIGN: Prospective, nonrandomized analysis of the treatment method. PARTICIPANTS: A total of 188 retinoblastomas in 80 eyes of 58 patients who were treated with thermotherapy. MAIN OUTCOME MEASURES: Tumor response and ocular adverse effects. RESULTS: Of 188 retinoblastomas treated with thermotherapy, mean tumor base was 3.0 mm and tumor thickness was 2.0 mm. Complete tumor regression was achieved in 161 tumors (85.6%), and 27 tumors (14.4%) developed recurrence. Using univariate analysis, the predictors of local tumor recurrence were male sex (P = .005), no color change ("no visible take") in tumor after treatment (P = .01), increasing number of treatment sessions (P = .002), and previous use of chemoreduction (P = .02). By multivariate analysis, the most important predictors of local tumor recurrence were male sex (P = .01) and previous use of chemoreduction (P = .03), the latter likely reflecting the fact that these tumors were initially larger with more ominous findings, and required chemoreduction therapy to reduce them to a size amenable to focal treatment with thermotherapy. When evaluating thermotherapy variables as a function of tumor size, it was apparent that larger tumors (> or =3.0-mm base) required greater energy and time than did smaller tumors (<3.0-mm base). Comparison of treatment variables for larger vs smaller tumors was as follows: number of treatment sessions, 3.3 vs 2.3; spot size, 1.7 vs 1.3 mm; power, 540 vs 370 mW; treatment duration, 49 vs 14 minutes; and coupling of thermotherapy with chemotherapy, 79% vs 48% of cases (P < or =.001 for each variable). Complications of thermotherapy in the 80 eyes included focal iris atrophy in 29 eyes (36%), peripheral focal lens opacity in 19 eyes (24%), retinal traction in 4 eyes (5%), retinal vascular obstruction in 2 eyes (2%), and transient localized serous retinal detachment in 2 eyes (2%). There were no cases of corneal scarring, central lens opacity, iris or retinal neovascularization, or rhegmatogenous retinal detachment. All eyes with focal lens opacity demonstrated adjacent focal iris atrophy. By multivariate analysis, the predictors of thermotherapy-induced focal iris atrophy were increasing number of treatment sessions (P = .001) and increasing tumor base (P = .02). CONCLUSIONS: Thermotherapy is used for relatively small retinoblastomas without associated vitreous or subretinal seeds. This treatment provides satisfactory control for selected retinoblastomas, with 86% of tumors demonstrating lasting regression. Tumors that measure 3.0 mm or larger in base at the time of thermotherapy require more intense treatment than smaller tumors and are at greatest risk for ocular complications such as focal iris atrophy and focal paraxial lens opacity